

Wenyan Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8069598/publications.pdf>

Version: 2024-02-01

40
papers

1,601
citations

331670

21
h-index

315739

38
g-index

40
all docs

40
docs citations

40
times ranked

2639
citing authors

#	ARTICLE	IF	CITATIONS
1	Pevedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. <i>Frontiers in Oncology</i> , 2022, 12, 822039.	2.8	4
2	Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors. <i>BMC Surgery</i> , 2022, 22, 160.	1.3	5
3	FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. <i>Redox Biology</i> , 2021, 38, 101807.	9.0	135
4	SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. <i>Cancer Letters</i> , 2021, 499, 265-278.	7.2	16
5	FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 997-1008.	2.0	5
6	MTAP Deficiency Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. <i>Cancer Research</i> , 2021, 81, 4964-4980.	0.9	15
7	Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e398.	4.0	1
8	ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. <i>Cancer Cell International</i> , 2021, 21, 514.	4.1	5
9	SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 1614-1624.	2.0	7
10	Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. <i>Oncogene</i> , 2020, 39, 6572-6588.	5.9	21
11	Ferroptosis: Final destination for cancer?. <i>Cell Proliferation</i> , 2020, 53, e12761.	5.3	73
12	Pin1 promotes pancreatic cancer progression and metastasis by activation of NF- κ B/IL-18 feedback loop. <i>Cell Proliferation</i> , 2020, 53, e12816.	5.3	32
13	Function and regulation of FoxO/WD repeat-containing protein 7 (Review). <i>Oncology Letters</i> , 2020, 20, 1526-1534.	1.8	7
14	Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. <i>American Journal of Cancer Research</i> , 2020, 10, 1182-1193.	1.4	16
15	Management of solid pseudopapillary neoplasms of pancreas: A single center experience of 243 consecutive patients. <i>Pancreatology</i> , 2019, 19, 681-685.	1.1	38
16	Laparoscopic pancreaticoduodenectomy: are the best times coming?. <i>World Journal of Surgical Oncology</i> , 2019, 17, 81.	1.9	23
17	UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. <i>Cancer Letters</i> , 2019, 452, 226-236.	7.2	99
18	Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. <i>Cancer Cell International</i> , 2019, 19, 49.	4.1	19

#	ARTICLE	IF	CITATIONS
19	PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. <i>Cell Communication and Signaling</i> , 2019, 17, 30.	6.5	72
20	Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. <i>Cell Proliferation</i> , 2019, 52, e12603.	5.3	29
21	FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 2650-2664.	1.4	10
22	TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1 α axis and indicates prognosis in pancreatic cancer. <i>Cell Death and Disease</i> , 2018, 9, 321.	6.3	45
23	<scp>dCK</scp> negatively regulates the <scp>NRF</scp>2/<scp>ARE</scp> axis and <scp>ROS</scp> production in pancreatic cancer. <i>Cell Proliferation</i> , 2018, 51, e12456.	5.3	22
24	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. <i>Theranostics</i> , 2018, 8, 5072-5087.	10.0	139
25	Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Research</i> , 2017, 15, 201-212.	3.4	45
26	A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. <i>International Journal of Oncology</i> , 2017, 50, 1792-1800.	3.3	20
27	ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. <i>Cancer Letters</i> , 2017, 388, 303-311.	7.2	46
28	FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. <i>Oncology Reports</i> , 2017, 38, 2069-2077.	2.6	23
29	Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4591-4598.	2.0	92
30	Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Cancer</i> , 2017, 8, 3615-3622.	2.5	20
31	Energy sources identify metabolic phenotypes in pancreatic cancer. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 969-979.	2.0	24
32	Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 177-188.	7.4	18
33	Critical role of oncogenic KRAS in pancreatic cancer (Review). <i>Molecular Medicine Reports</i> , 2016, 13, 4943-4949.	2.4	27
34	New insights into perineural invasion of pancreatic cancer: More than pain. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 111-122.	7.4	39
35	FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3950-3960.	7.0	72
36	ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. <i>Cancer Letters</i> , 2016, 374, 127-135.	7.2	104

#	ARTICLE	IF	CITATIONS
37	Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. <i>Surgery</i> , 2015, 158, 1211-1218.	1.9	21
38	Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. <i>Cancer Letters</i> , 2015, 360, 227-233.	7.2	37
39	ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. <i>Cell Research</i> , 2015, 25, 561-573.	12.0	112
40	LSD1 sustains pancreatic cancer growth via maintaining HIF1 α -dependent glycolytic process. <i>Cancer Letters</i> , 2014, 347, 225-232.	7.2	63